We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Join our healthcare community
Understand how Cosentyx (secukinumab) may impact reproductive health, including considerations for pregnancy, breastfeeding, and fertility in both men and women. Get informed about safe use and family planning.
Cosentyx (secukinumab) is a widely used biologic medication prescribed for various autoimmune conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. While highly effective in managing these chronic inflammatory diseases, understanding its implications for reproductive health is crucial for individuals who are planning a family, are pregnant, or are breastfeeding. This comprehensive guide delves into how Cosentyx may affect fertility, pregnancy, and breastfeeding, providing essential information to help you make informed decisions in consultation with your healthcare provider.
Cosentyx is a human monoclonal antibody that specifically targets interleukin-17A (IL-17A), a cytokine that plays a key role in inflammation and the development of autoimmune diseases. By blocking IL-17A, Cosentyx helps to reduce inflammation and alleviate symptoms associated with conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is typically administered via subcutaneous injection.
As a biologic medication, Cosentyx works by modulating specific parts of the immune system. This targeted action is what makes it effective for autoimmune conditions. However, because it is a large protein molecule, its presence in the body, particularly during critical reproductive stages, warrants careful consideration. The drug's ability to cross the placenta or be excreted into breast milk is a primary concern for reproductive health.
For individuals taking Cosentyx who are pregnant or planning to become pregnant, the decision to continue, adjust, or discontinue treatment requires careful consideration of potential risks versus the benefits of disease control.
Current data on the use of Cosentyx during human pregnancy is limited. Most of the available information comes from post-marketing surveillance and pregnancy registries, rather than controlled clinical trials in pregnant individuals. Animal studies have shown no direct evidence of harm to the fetus at doses higher than those used in humans. However, animal studies do not always predict human response.
Cosentyx, being an IgG1 antibody, is known to cross the placenta, especially during the second and third trimesters. This means the developing fetus will be exposed to the medication. The potential effects of this exposure on fetal development and the infant's immune system after birth are areas of ongoing research and concern.
To gather more information about the safety of medications like Cosentyx during pregnancy, healthcare providers often encourage enrollment in pregnancy registries, such as the MotherToBaby Pregnancy Studies. These registries collect observational data from individuals who have taken medications during pregnancy, helping to assess potential risks and provide better guidance for future patients and clinicians.
The decision to breastfeed while taking Cosentyx also requires careful consideration due to the potential for the drug to pass into breast milk.
Like other monoclonal antibodies, Cosentyx is expected to be present in human breast milk. However, the amount that transfers into milk is generally low. Furthermore, the extent to which an infant absorbs these large protein molecules through their gastrointestinal tract is often limited, as they may be broken down during digestion.
While the risk of systemic exposure to the infant through breast milk is considered low, potential effects on the infant's developing immune system are a theoretical concern. There have been no reports of adverse effects in breastfed infants whose mothers were taking Cosentyx, but long-term data are still limited.
Concerns about medication impacting fertility are common for individuals planning a family. For Cosentyx, direct evidence of an impact on fertility is limited.
There is no strong evidence from clinical trials or post-marketing data suggesting that Cosentyx directly impairs female fertility. However, the underlying inflammatory conditions that Cosentyx treats (e.g., psoriatic arthritis, ankylosing spondylitis) can sometimes affect reproductive health and fertility due to chronic inflammation and disease activity.
Similarly, there is no significant data to suggest that Cosentyx directly affects male fertility, such as sperm count or quality. Men taking Cosentyx should generally not be concerned about a direct impact on their ability to conceive. As with women, the underlying inflammatory disease itself could potentially have an indirect impact on male reproductive health.
If you have concerns about fertility, whether related to Cosentyx or your underlying condition, it is vital to discuss these with your doctor. They can evaluate your specific situation, provide personalized advice, and, if necessary, refer you to a fertility specialist.
Effective management of your autoimmune condition is crucial for your overall health and can positively impact your reproductive health and pregnancy outcomes. Open communication with your healthcare team is key.
If you are planning to conceive, pre-conception counseling with your rheumatologist, dermatologist, or a maternal-fetal medicine specialist is highly recommended. This allows for a proactive discussion about your medication regimen, disease activity, and any necessary adjustments to optimize your health before and during pregnancy.
If you are sexually active and not planning a pregnancy, it is important to use effective contraception while taking Cosentyx. This helps prevent unintended pregnancies, especially given the limited data on Cosentyx's safety during pregnancy.
In some cases, your doctor might consider adjusting your treatment plan. This could involve switching to a medication with more established safety data in pregnancy, temporarily discontinuing Cosentyx, or modifying the dosing schedule, depending on the severity of your condition and individual circumstances.
Data on Cosentyx use during human pregnancy is limited. While animal studies have not shown harm, human studies are ongoing, largely through pregnancy registries. The decision to use Cosentyx during pregnancy involves carefully weighing the benefits of disease control against potential risks to the fetus, in consultation with your doctor.
Cosentyx is expected to pass into breast milk in low amounts. The risk of systemic exposure to the infant is considered low due to limited absorption through the infant's gut. Discuss with your doctor to assess your individual situation and monitor the infant if you choose to breastfeed.
There is no significant evidence from clinical data to suggest that Cosentyx directly impairs male fertility (e.g., sperm count or quality). Any fertility concerns should be discussed with a healthcare provider.
Contact your doctor immediately. They will assess your condition, discuss the potential risks and benefits, and help you determine the safest course of action for both your health and the pregnancy.
Depending on your condition and its severity, your doctor may discuss alternative medications or treatment strategies that have more established safety profiles during pregnancy and breastfeeding. This is a personalized discussion based on your medical history.
Navigating treatment for chronic autoimmune conditions while planning for or experiencing pregnancy and breastfeeding can be complex. Cosentyx, an effective treatment for many, requires careful consideration regarding reproductive health. Open and honest communication with your healthcare team – including your rheumatologist, dermatologist, obstetrician, and any other specialists – is paramount. Together, you can develop a personalized plan that prioritizes both your health and the well-being of your family, ensuring you have the most up-to-date and relevant information to make informed decisions.
Visit Hospital
Near You
Learn about kidney transplant options in Narendrapur, recovery, and donor criteria. Expert insights for informed decisions.
May 19, 2026
Explore LASIK eye surgery in Madhepura. Learn about eligibility, the procedure, benefits, risks, and costs from trusted specialists.
May 19, 2026
Explore LASIK surgery in Nalanda. Understand eligibility, the procedure, recovery, and costs for vision correction at leading eye clinics.
May 19, 2026